Management options for node-positive muscle-invasive bladder cancer.

Hyma Polimera(Penn State Milton S. Hershey Medical Center), Monika Joshi(Pennsylvania State University), Priyanka Bhatia(Department of Biotechnology), Stuthi Perimbeti(Roswell Park Comprehensive Cancer Center), Megan Wheelden(Penn State Milton S. Hershey Medical Center), Joshua I. Warrick(Penn State Milton S. Hershey Medical Center)
PubMed
October 1, 2024
Cited by 0

Related Papers

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|381
FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
|Scientific Reports|2016|147
Platelet-rich fibrin: the benefits
|British Journal of Oral and Maxillofacial Surgery|2015|76
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
|PLoS ONE|2015|61
Micronutrient seed priming: new insights in ameliorating heavy metal stress
|Environmental Science and Pollution Research|2022|22